FIELD: medicine.
SUBSTANCE: invention relates to a fused protein containing an amino acid sequence according to SEQ ID NO:16, where the fused protein is an immunomodulatory agent that increases or enhances an immune function by inhibiting ligand binding to LAIR-1, thereby reducing LAIR-1 expression, ligand binding, cross-linking, signal transmission or a combination thereof. A pharmaceutical composition containing the specified fused protein is also proposed, which is intended to stimulate an immune response to inhibit the survival of malignant cells, or to stimulate an antitumor immune response to malignant cells, or to stimulate an immune response against bacterial infections.
EFFECT: fused protein can be used to treat diseases such as ovarian cancer, lymphoma or bacterial infection.
19 cl, 25 dwg, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
